- 专利标题: Fused pentacyclic imidazole derivatives as modulators of TNF activity
-
申请号: US16086408申请日: 2017-03-31
-
公开(公告)号: US10654861B2公开(公告)日: 2020-05-19
- 发明人: Michael Louis Robert Deligny , Jag Paul Heer , Jean Keyaerts , Luce Elsa Lepissier , Martin Alexander Lowe
- 申请人: UCB Biopharma SRL , Sanofi
- 申请人地址: BE Brussels
- 专利权人: UCB Biopharma SRL
- 当前专利权人: UCB Biopharma SRL
- 当前专利权人地址: BE Brussels
- 代理机构: McDonnell Boehnen Hulbert & Berghoff LLP
- 优先权: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@170c79d9
- 国际申请: PCT/EP2017/057767 WO 20170331
- 国际公布: WO2017/167994 WO 20171005
- 主分类号: C07D487/18
- IPC分类号: C07D487/18 ; C07D487/04
摘要:
A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
公开/授权文献
信息查询